NCT03856996View on ClinicalTrials.gov

A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

March 16, 2021

Study Completion Date

September 7, 2021

Conditions
HIV Infections
Interventions
BIOLOGICAL

Stable CH505TF gp120

Administered by IM injection in the deltoid of the non-dominant arm

BIOLOGICAL

Transient CH505TF gp120

Administered by IM injection in the deltoid of the non-dominant arm

BIOLOGICAL

Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)

Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm

Trial Locations (3)

30030

The Hope Clinic of the Emory Vaccine Center CRS, Decatur

02115-6110

Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston

37232-2582

Vanderbilt Vaccine (VV) CRS, Nashville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03856996 - A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells | Biotech Hunter | Biotech Hunter